Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice

Circulation

Volumn 112, Issue 18, 2005, Pages 2875-2882

  Phan, Olivier ^a   Ivanovski, Ognen ^a   Nguyen Khoa, Thao ^a   Mothu, Nadya ^a   Angulo, Jesus ^b   Westenfeld, Ralf ^c   Ketteler, Markus ^c   Meert, Natalie ^d   Maizel, Julien ^e   Nikolov, Igor G ^g   Vanholder, Raymond ^d   Lacour, Bernard ^a   Drücke, Tilman B ^a   Massy, Ziad A ^e,f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e INSERM   (France)

^f UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^g University of Picardie and University Hospital ^*

Author keywords

Atherosclerosis; Calcium; Oxidative stress; Phosphates; Uremia

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN E; CALCIUM; CHOLESTEROL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CALCIFICATION; ARTERY MEDIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; INTIMA; MINERAL METABOLISM; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; STAINING; UREMIA;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; COLLAGEN; DISEASE PROGRESSION; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES; PLACEBOS; POLYAMINES; TYROSINE; UREMIA;

EID: 27844465098     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA105.541854     Document Type: Article

References (32)

1. Drueke TB, Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl. 2001;78:S114-S119.
2. Massy ZA, Nguyen-Khoa T, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant. 1999;14:2392-2397.
3. Drueke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif. 2002;20:494-497.
4. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
5. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16-S23.
6. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
7. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol. 2003;14:2466-2474.
8. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311-316.
9. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol. 2005;16:109-116.
10. Dhondt AW, Vanholder RC, De Smet RV, Claus SA, Waterloos MA, Glorieux GL, Delanghe JR, Lameire NH. Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. Kidney Int. 2003;63:1540-1547.
11. Mozes G, Friedman N, Shainkin-Kestenbaum R. Serum amyloid A: an extremely sensitive marker for intensity of tissue damage in trauma patients and indicator of acute response in various diseases. J Trauma. 1989;29:71-74.
12. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001;89:41e-45e.
13. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drueke TB, Massy ZA. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int. 2005;67:2288-2294.
14. Angulo J, Nguyen-Koa T, Massy Z, Drueke T, Serra J. Morphological quantification of aortic calcification from low magnification images. Image Anal Stereol. 2003;22:81-89.
15. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther. 2003;10:133-145.
16. Liang K, Kim CH, Vaziri ND. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol. 2004;288:F539-F544.
17. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001;103:3099-3104.
18. Ketteler M, Bongartz P, Westenfeld R, Ernst Wildberger J, Horst Mahnken A, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-833.
19. Moe SM, Chen NX. Inflammation and vascular calcification. Blood Purif. 2005;23:64-71.
20. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: the immune system and atherogenesis: lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005;46:389-403.
21. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arterio-sclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003;23:307-314.
22. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
23. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14:S305-S309.
24. Schwarz U. Buzello M. Ritz E, Stein G, Raabe G, Wiest G, Mall G. Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218-223.
25. Moe SM. Duan D, Doehle BP. O'Neill KD. Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003-1011.
26. Giachelli CM. Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol. 1999;154:671-675.
27. Jono S, McKee MD. Murry CE. Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:10e-17e.
28. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42:1253-1259.
29. De Smet R, Thermote F, Lameire N. Vanholder R. Sevelamer hydrochloride (Renagel) adsorbs the uremic compounds indoxyl sulfate, indole and p-cresol. J Am Soc Nephrolol. 2004;15:505. Abstract.
30. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunei P. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004;65:442-451.
31. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290-295.
32. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunei P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-1943.